RemeGen's Antibody-Drug Conjugate Gets FDA Fast Track Designation for Ovarian Cancer

RC88 is under evaluation for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *